Recent Additions

This page includes the documents that were newly added to the repository within the last 30 days.

All these words:

This exact word or phrase:

Any of these words:

None of these words:

Language:

Publication Date Range:

Visit our Help Page for additional assistance

Select a Range:

Select a Format:

Custom Search Builder:

Custom Search Box

Visit our Help Page for additional assistance

Showing 821 - 840 of 1003 results

Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Unknown serogroup. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities re ...

07/31/2026

Supporting Files

Title : Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258374
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Unknown serogroup. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-10540.pdf AN - cdc:258374 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Meningococcal Disease KW - Meningococcal Disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Meningococcal disease, Unknown serogroup (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258374 ER -
Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Other serogroups. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities rep ...

07/31/2026

Supporting Files

Title : Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258373
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Other serogroups. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-10530.pdf AN - cdc:258373 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Meningococcal Disease KW - Meningococcal Disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Meningococcal disease, Other serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258373 ER -
Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Serogroup B. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report c ...

07/31/2026

Supporting Files

Title : Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258372
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Serogroup B. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50256.pdf AN - cdc:258372 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Meningococcal Disease KW - Meningococcal Disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Meningococcal disease, Serogroup B (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258372 ER -
Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Serogroups ACWY. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities repo ...

07/31/2026

Supporting Files

Title : Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258371
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, Serogroups ACWY. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50255.pdf AN - cdc:258371 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Meningococcal Disease KW - Meningococcal Disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Meningococcal disease, Serogroups ACWY (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258371 ER -
Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, All serogroups. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities repor ...

07/31/2026

Supporting Files

Title : Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258370
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Meningococcal disease, All serogroups. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50254.pdf AN - cdc:258370 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Meningococcal Disease KW - Meningococcal Disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Meningococcal disease, All serogroups (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258370 ER -
Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Malaria. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health ...

07/31/2026

Supporting Files

Title : Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258369
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Malaria. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50253.pdf AN - cdc:258369 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Malaria KW - Malaria KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Malaria (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258369 ER -
Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Hepatitis A, Confirmed. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to ...

07/31/2026

Supporting Files

Title : Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258368
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Hepatitis A, Confirmed. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50251.pdf AN - cdc:258368 CY - Atlanta, GA IS - 29 KW - Hepatitis A KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Hepatitis A KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Hepatitis A, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258368 ER -
Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Hepatitis B, perinatal, Confirmed. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report co ...

07/31/2026

Supporting Files

Title : Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258367
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Hepatitis B, perinatal, Confirmed. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50250.pdf AN - cdc:258367 CY - Atlanta, GA IS - 29 KW - Hepatitis B, Chronic KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Hepatitis B, Chronic KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Hepatitis B, perinatal, Confirmed (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258367 ER -
Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Arboviral diseases, Chikungunya virus disease. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entiti ...

07/31/2026

Supporting Files

Title : Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258366
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Arboviral diseases, Chikungunya virus disease. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-50249.pdf AN - cdc:258366 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Chikungunya virus KW - Chikungunya virus KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Arboviral diseases, Chikungunya virus disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258366 ER -
Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Varicella disease. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to publ ...

07/31/2026

Supporting Files

Title : Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258365
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Varicella disease. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-10073.pdf AN - cdc:258365 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Varicella disease KW - Chickenpox / prevention & control KW - Chickenpox / prevention & control KW - Varicella disease KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Varicella disease (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258365 ER -
Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System.

07/25/2026 | National Notifiable Diseases: Infectious Weekly Tables

This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Brucellosis. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public hea ...

07/31/2026

Supporting Files

Title : Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. Published Date : 07/25/2026 Series : National Notifiable Diseases: Infectious Weekly Tables URL : https://stacks.cdc.gov/view/cdc/258364
Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. (2026). Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026. 2026(29).

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" 2026, no. 29 (2026)

Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. "Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026" vol. 2026, no. 29, 2026
Export RIS Citation Information. TY - Weekly Tables A2 - Centers for Disease Control and Prevention (U.S.). Center for Surveillance, Epidemiology, and Laboratory Services. National Notifiable Diseases Surveillance System. AB - This data includes weekly cases of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents, specifically covering: Brucellosis. The Weekly data are considered provisional and collected locally due to state, territorial, and local regulations. Healthcare providers, medical labs, and other entities report conditions to public health departments, varying by jurisdiction. Case notifications for national notifiable conditions are voluntarily submitted to CDC. NNDSS data are provisional and subject to change until reconciled with state and territorial providers. Weekly cumulative counts may increase or decrease as updates occur. Finalized annual data often differ from provisional counts. CDC aggregates data for national notifiable diseases and conditions on a weekly and annual basis. To see specific surveillance Case Definitions for this disease, go to: https://ndc.services.cdc.gov/ AB - 2026-29-10358.pdf AN - cdc:258364 CY - Atlanta, GA IS - 29 KW - Data Collection KW - Brucellosis KW - Public Health Surveillance KW - Communicable Diseases/epidemiology KW - Disease Notification KW - Brucellosis KW - Communicable Diseases/epidemiology KW - Data Collection KW - Disease Notification KW - Public Health Surveillance LA - eng PY - 07/25/2026 T3 - National Notifiable Diseases: Infectious Weekly Tables TI - Brucellosis (Week 29) Weekly cases* of notifiable diseases, United States, U.S. Territories, and Non-U.S. Residents week ending July 25, 2026 VL - 2026 UR - https://stacks.cdc.gov/view/cdc/258364 ER -
The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion

2021/02/01 | Standardized Infection Ratio (SIR) Guide

The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document ...

07/31/2026

Title : The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021 Corporate Authors(s) : National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion Published Date : 2021/02/01 Pages in Document : 53 pdf pages Series : Standardized Infection Ratio (SIR) Guide URL : https://stacks.cdc.gov/view/cdc/258363
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion (2021). The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021.

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021" (2021)

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021" , 2021
Export RIS Citation Information. TY - Pamphlet (or booklet) A2 - National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion AB - The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document is intended to serve both as guidance for those who are new to this metric as well as a useful reference for more experienced infection prevention professionals. AB - What is the SIR? The standardized infection ratio (SIR) is a summary measure used to track HAIs at a national, state, or local level over time. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. The method of calculating an SIR is similar to the method used to calculate the Standardized Mortality Ratio (SMR), a summary statistic widely used in public health to analyze mortality data. In HAI data analysis, the SIR compares the actual number of HAIs reported to the number that would be predicted, given the standard population (i.e., NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. In other words, an SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, an SIR less than 1.0 indicates that fewer HAIs were observed than predicted. SIRs are currently calculated in NHSN for the following HAI types: central line-associated bloodstream infections (CLABSI), mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), Clostridioides difficile infections (CDI), methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA), and ventilator-associated events (VAE). AN - cdc:258363 CY - Atlanta, GA KW - Hospitals, Rehabilitation KW - Health Care Facilities KW - Risk Factors KW - Hospitals KW - Surgical Wound Infection KW - Disease Transmission, Infectious KW - Cross Infection KW - Standardized Infection Ratios (SIRs) KW - Cross Infection KW - Disease Transmission, Infectious KW - Health Care Facilities KW - Hospitals KW - Hospitals, Rehabilitation KW - Risk Factors KW - Surgical Wound Infection LA - eng PB - Centers for Disease Control and Prevention (CDC) (U.S.) PY - 2021/02/01 T3 - Standardized Infection Ratio (SIR) Guide TI - The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated February 2021 UR - https://stacks.cdc.gov/view/cdc/258363 ER -
The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion

2019/03/01 | Standardized Infection Ratio (SIR) Guide

The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document ...

07/31/2026

Title : The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019 Corporate Authors(s) : National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion Published Date : 2019/03/01 Pages in Document : 49 pdf pages Series : Standardized Infection Ratio (SIR) Guide URL : https://stacks.cdc.gov/view/cdc/258362
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion (2019). The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019.

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019" (2019)

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019" , 2019
Export RIS Citation Information. TY - Pamphlet (or booklet) A2 - National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion AB - The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document is intended to serve both as guidance for those who are new to this metric as well as a useful reference for more experienced infection prevention professionals. AB - What is the SIR? The standardized infection ratio (SIR) is a summary measure used to track HAIs at a national, state, or local level over time. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. The method of calculating an SIR is similar to the method used to calculate the Standardized Mortality Ratio (SMR), a summary statistic widely used in public health to analyze mortality data. In HAI data analysis, the SIR compares the actual number of HAIs reported to the number that would be predicted, given the standard population (i.e., NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. In other words, an SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, an SIR less than 1.0 indicates that fewer HAIs were observed than predicted. SIRs are currently calculated in NHSN for the following HAI types: central line-associated bloodstream infections (CLABSI), mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), Clostridioides difficile infections (CDI), methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA), and ventilator-associated events (VAE). AN - cdc:258362 CY - Atlanta, GA KW - Hospitals, Rehabilitation KW - Risk Factors KW - Health Care Facilities KW - Hospitals KW - Surgical Wound Infection KW - Disease Transmission, Infectious KW - Cross Infection KW - Standardized Infection Ratios (SIRs) KW - Cross Infection KW - Disease Transmission, Infectious KW - Health Care Facilities KW - Hospitals KW - Hospitals, Rehabilitation KW - Risk Factors KW - Surgical Wound Infection LA - eng PB - Centers for Disease Control and Prevention (CDC) (U.S.) PY - 2019/03/01 T3 - Standardized Infection Ratio (SIR) Guide TI - The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated March 2019 UR - https://stacks.cdc.gov/view/cdc/258362 ER -
The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion

2018/08/01 | Standardized Infection Ratio (SIR) Guide

The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document ...

07/31/2026

Title : The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018 Corporate Authors(s) : National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion Published Date : 2018/08/01 Pages in Document : 43 pdf pages Series : Standardized Infection Ratio (SIR) Guide URL : https://stacks.cdc.gov/view/cdc/258361
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion (2018). The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018.

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018" (2018)

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018" , 2018
Export RIS Citation Information. TY - Pamphlet (or booklet) A2 - National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion AB - The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document is intended to serve both as guidance for those who are new to this metric as well as a useful reference for more experienced infection prevention professionals. AB - What is the SIR? The standardized infection ratio (SIR) is a summary measure used to track HAIs at a national, state, or local level over time. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. The method of calculating an SIR is similar to the method used to calculate the Standardized Mortality Ratio (SMR), a summary statistic widely used in public health to analyze mortality data. In HAI data analysis, the SIR compares the actual number of HAIs reported to the number that would be predicted, given the standard population (i.e., NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. In other words, an SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, an SIR less than 1.0 indicates that fewer HAIs were observed than predicted. SIRs are currently calculated in NHSN for the following HAI types: central line-associated bloodstream infections (CLABSI), mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), Clostridioides difficile infections (CDI), methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA), and ventilator-associated events (VAE). AN - cdc:258361 CY - Atlanta, GA KW - Hospitals, Rehabilitation KW - Risk Factors KW - Health Care Facilities KW - Hospitals KW - Surgical Wound Infection KW - Disease Transmission, Infectious KW - Cross Infection KW - Standardized Infection Ratios (SIRs) KW - Cross Infection KW - Disease Transmission, Infectious KW - Health Care Facilities KW - Hospitals KW - Hospitals, Rehabilitation KW - Risk Factors KW - Surgical Wound Infection LA - eng PB - Centers for Disease Control and Prevention (CDC) (U.S.) PY - 2018/08/01 T3 - Standardized Infection Ratio (SIR) Guide TI - The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: Updated August 2018 UR - https://stacks.cdc.gov/view/cdc/258361 ER -
The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion

2016/12/01 | Standardized Infection Ratio (SIR) Guide

The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document ...

07/31/2026

Title : The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016 Corporate Authors(s) : National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion Published Date : 2016/12/01 Pages in Document : 40 pdf pages Series : Standardized Infection Ratio (SIR) Guide URL : https://stacks.cdc.gov/view/cdc/258360
National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion (2016). The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016.

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016" (2016)

National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion "The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016" , 2016
Export RIS Citation Information. TY - Pamphlet (or booklet) A2 - National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Healthcare Quality Promotion AB - The Standardized Infection Ratio (SIR) is the primary summary measure used by the National Healthcare Safety Network (NHSN) to track healthcareassociated infections (HAIs). As NHSN grows, both in its user-base and surveillance capability, the SIR continues to evolve. Highlighting the SIR and changes resulting from an updated baseline, this document is intended to serve both as guidance for those who are new to this metric as well as a useful reference for more experienced infection prevention professionals. AB - What is the SIR? The standardized infection ratio (SIR) is a summary measure used to track HAIs at a national, state, or local level over time. The SIR adjusts for various facility and/or patient-level factors that contribute to HAI risk within each facility. The method of calculating an SIR is similar to the method used to calculate the Standardized Mortality Ratio (SMR), a summary statistic widely used in public health to analyze mortality data. In HAI data analysis, the SIR compares the actual number of HAIs reported to the number that would be predicted, given the standard population (i.e., NHSN baseline), adjusting for several risk factors that have been found to be significantly associated with differences in infection incidence. In other words, an SIR greater than 1.0 indicates that more HAIs were observed than predicted; conversely, an SIR less than 1.0 indicates that fewer HAIs were observed than predicted. SIRs are currently calculated in NHSN for the following HAI types: central line-associated bloodstream infections (CLABSI), mucosal barrier injury laboratory-confirmed bloodstream infections (MBI-LCBI), catheter-associated urinary tract infections (CAUTI), surgical site infections (SSI), Clostridioides difficile infections (CDI), methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA), and ventilator-associated events (VAE). AN - cdc:258360 CY - Atlanta, GA KW - Hospitals, Rehabilitation KW - Risk Factors KW - Health Care Facilities KW - Hospitals KW - Disease Transmission, Infectious KW - Surgical Wound Infection KW - Cross Infection KW - Standardized Infection Ratios (SIRs) KW - Cross Infection KW - Disease Transmission, Infectious KW - Health Care Facilities KW - Hospitals KW - Hospitals, Rehabilitation KW - Risk Factors KW - Surgical Wound Infection LA - eng PB - Centers for Disease Control and Prevention (CDC) (U.S.) PY - 2016/12/01 T3 - Standardized Infection Ratio (SIR) Guide TI - The NHSN Standardized Infection Ratio (SIR): A Guide to the SIR: December 2016 UR - https://stacks.cdc.gov/view/cdc/258360 ER -
MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021]

Centers for Disease Control and Prevention (U.S.)

08/06/2021 | Vaccine Information Statement

א VIS אָדער וואַקצין אינפֿאָרמאַציע דערקלערונג איז אַ דאָקומענט, פּראָדוצירט פֿון CDC, וואָס אינפֿאָרמירט וואַקצין־קריגער - אָדער זייערע עלטערן אָדער געזעצלעכע פֿאַרטרעטער - וועגן די בענעפֿיטן און ריזיקעס פֿון אַ וואַקצין וואָס זיי קריגן. אַלע וואַקצין־צושטעלער, עפֿנטלעך אָדער פּריוואַט, זענען פֿאַרפֿליכטעט לויט דעם National Vaccine Childhood Injur ...

07/29/2026

Supporting Files

Title : MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021] Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : 08/06/2021 Pages in Document : 2 pdf pages Series : Vaccine Information Statement;וואַקצין אינפֿאָרמאַציע דערקלערונג; URL : https://stacks.cdc.gov/view/cdc/258359
Centers for Disease Control and Prevention (U.S.) (2021). MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021].

Centers for Disease Control and Prevention (U.S.) "MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021]" (2021)

Centers for Disease Control and Prevention (U.S.) "MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021]" , 2021
Export RIS Citation Information. TY - Array A2 - Centers for Disease Control and Prevention (U.S.) AB - א VIS אָדער וואַקצין אינפֿאָרמאַציע דערקלערונג איז אַ דאָקומענט, פּראָדוצירט פֿון CDC, וואָס אינפֿאָרמירט וואַקצין־קריגער - אָדער זייערע עלטערן אָדער געזעצלעכע פֿאַרטרעטער - וועגן די בענעפֿיטן און ריזיקעס פֿון אַ וואַקצין וואָס זיי קריגן. אַלע וואַקצין־צושטעלער, עפֿנטלעך אָדער פּריוואַט, זענען פֿאַרפֿליכטעט לויט דעם National Vaccine Childhood Injury Act <a href="https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapXIX-part2-subpartc-sec300aa-26.pdf"_blank">(NCVIA - 42 U.S.C. § 300aa-26)</a> צו געבן דעם פּאַסיקן VIS צום פּאַציענט (אָדער עלטער אָדער געזעצלעכן פֿאַרטרעטער) איידער יעדער דאָזע פֿון ספּעציפֿישע וואַקצינען. דער פּאַסיקער VIS מוז ווערן געגעבן איידער דער וואַקצינאַציע, און מוז ווערן געגעבן איידער יעדער דאָזע פֿון אַ מער־דאָזע סעריע. עס מוז ווערן געגעבן אומאָפּהענגיק פֿון דעם עלטער פֿונעם קריגער: פֿון <a href="https://www.cdc.gov/vaccines/hcp/about-vis/index.html"target="_blank">https://www.cdc.gov/vaccines/hcp/about-vis/index.html</a>. AB - VISן זענען איבערגעזעצט געוואָרן אין אַרום 40 שפּראַכן. די קען מען געפֿינען אויף דער וועבזייַט פֿון CDC'ס שותּף, <a href="https://www.immunize.org/vis/"target="_blank">https://www.immunize.org/vis/</a>. ניט יעדער VIS איז איבערגעזעצט געוואָרן אין יעדער שפּראַך. AB - פֿאַר וואָס זיך וואַקצינירן? די MMRV וואַקצין קען פֿאַרמיידן מאָזלען, חזירייַט (mumps), רויטלעך, און וויקן (varicella). מאָזלען (M) פֿאַראורזאַכט פֿיבער, הוסטן, אַ רינענדיקע נאָז, און רויטע, טרערנדיקע אויגן, וואָס ווערט אָפֿט געפֿאָלגט מיט אַ אויסשלאָג וואָס באַדעקט דעם גאַנצן קערפּער. עס קען פֿירן צו קאָנוואַלסיעס (אָפֿט פֿאַרבונדן מיט פֿיבער), אויער־אינפֿעקציעס, דורכפֿאַל, און לונגען־אָנצינדונג. זעלטן, קען מאָזלען פֿאַראורזאַכן מוח־שאָדן אָדער טויט. חזירייַט (M) פֿאַראורזאַכט פֿיבער, קאָפּ־וויי, מוסקל־ווייטיקן, מידקייט, אַ פֿאַרלוסט פֿון אַפּעטיט, און אָנגעשוואָלענע און וויי־טוענדיקע שפּייעכץ־דריזלען אונטער די אויערן. עס קען פֿירן צו טויבקייט, אָנשוועלונג פֿון די מוח און/אָדער די רוקן־מאַרך־צודעק, ווייטיקדיקע אָנשוועלונג פֿון די טעסטיקלען אָדער עגגלאָרס, און, זייער זעלטן, טויט. רויטלעך (R) פֿאַראורזאַכט פֿיבער, אַ וויי־טוענדיקן האַלדז, אַן אויסשלאָג, קאָפּ־וויי, און אויג־ריצן. עס קען פֿאַראורזאַכן אַרטריטיס ביי ביז צו האַלב פֿון יונגע און דערוואַקסענע פֿרויען. אויב אַ פֿרוי קריגט רויטלעך בשעת זי איז מעוברת, קען זי האָבן אַ פֿעללגעבורט, אָדער דאָס קינד קען געבוירן ווערן מיט ערנסטע געבוירן־דעפֿעקטן. וויקן (V), אויך גערופֿן "פּאָקן", פֿאַראורזאַכט אַ קרעצנדיקן אויסשלאָג, צוזאַמען מיט פֿיבער, מידקייט, אַ פֿאַרלוסט פֿון אַפּעטיט, און קאָפּ־וויי. עס קען פֿירן צו הויט־אינפֿעקציעס, לונגען־אָנצינדונג, אָנצינדונג פֿון בלוט־אָדערן, אָנשוועלונג פֿון די מוח און/אָדער די רוקן־מאַרך־צודעק, און אינפֿעקציע פֿון די בלוט, ביינער, אָדער געלענקען. עטלעכע מענטשן וואָס קריגן פּאָקן קריגן אַ ווייטיקדיקן אויסשלאָג גערופֿן "שינגלס" (אויך באַקאַנט ווי herpes zoster) יאָרן שפּעטער. רובֿ מענטשן וואָס ווערן וואַקצינירט מיט MMRV וועלן זײַן באַשיצט אויף אַ גאַנץ לעבן. וואַקצינען און הויכע ראַטעס פֿון וואַקצינאַציע האָבן געמאַכט די קרענק פֿיל ווייניקער פֿאַרשפּרייט אין די פֿאַראייניקטע שטאַטן. AN - cdc:258359 CY - Atlanta, Georgia KW - Measles / prevention & control KW - Vaccines KW - Chickenpox KW - Rubella / prevention & control KW - Chickenpox Vaccine KW - Chickenpox / prevention & control KW - Measles KW - Measles-Mumps-Rubella Vaccine / adverse effects KW - Mumps KW - Measles-Mumps-Rubella Vaccine KW - Rubella KW - Mumps / prevention & control KW - Chickenpox Vaccine / adverse effects KW - Varicella KW - Vaccines KW - Measles KW - Measles / prevention & control KW - Mumps KW - Mumps / prevention & control KW - Rubella KW - Rubella / prevention & control KW - Chickenpox KW - Chickenpox / prevention & control KW - Chickenpox Vaccine KW - Chickenpox Vaccine / adverse effects KW - Measles-Mumps-Rubella Vaccine KW - Measles-Mumps-Rubella Vaccine / adverse effects LA - yid PB - Centers for Disease Control and Prevention (U.S.) PY - 08/06/2021 T3 - Vaccine Information Statement TI - MMRV וואַקצין (מאָזלען, חזירייַט, רויטלעך, און וויקן): וואָס איר דאַרפֿט וויסן [2021] UR - https://stacks.cdc.gov/view/cdc/258359 ER -
MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021]

Centers for Disease Control and Prevention (U.S.)

08/06/2021 | Vaccine Information Statement

VIS یا ویکسین معلوماتی بیان ایک دستاویز ہے، جو CDC کی طرف سے تیار کی جاتی ہے، جو ویکسین حاصل کرنے والوں - یا ان کے والدین یا قانونی نمائندوں - کو ان کی وصول کردہ ویکسین کے فوائد اور خطرات کے بارے میں مطلع کرتی ہے۔ تمام ویکسین فراہم کنندگان، سرکاری ہوں یا نجی، نیشنل ویکسین چائلڈہڈ انجری ایکٹ https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pd ...

07/29/2026

Supporting Files

Title : MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021] Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : 08/06/2021 Pages in Document : 2 pdf pages Series : Vaccine Information Statement;ویکسین معلوماتی بیان; URL : https://stacks.cdc.gov/view/cdc/258358
Centers for Disease Control and Prevention (U.S.) (2021). MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021].

Centers for Disease Control and Prevention (U.S.) "MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021]" (2021)

Centers for Disease Control and Prevention (U.S.) "MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021]" , 2021
Export RIS Citation Information. TY - Array A2 - Centers for Disease Control and Prevention (U.S.) AB - VIS یا ویکسین معلوماتی بیان ایک دستاویز ہے، جو CDC کی طرف سے تیار کی جاتی ہے، جو ویکسین حاصل کرنے والوں - یا ان کے والدین یا قانونی نمائندوں - کو ان کی وصول کردہ ویکسین کے فوائد اور خطرات کے بارے میں مطلع کرتی ہے۔ تمام ویکسین فراہم کنندگان، سرکاری ہوں یا نجی، نیشنل ویکسین چائلڈہڈ انجری ایکٹ <a href="https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapXIX-part2-subpartc-sec300aa-26.pdf"_blank">(NCVIA - 42 U.S.C. § 300aa-26)</a> کے تحت پابند ہیں کہ مخصوص ویکسینز کی ہر خوراک سے پہلے مریض (یا والدین یا قانونی نمائندے) کو مناسب VIS فراہم کریں۔ مناسب VIS ویکسینیشن سے پہلے دیا جانا ضروری ہے، اور کثیر خوراکوں پر مشتمل سلسلے کی ہر خوراک سے پہلے دیا جانا ضروری ہے۔ یہ وصول کنندہ کی عمر سے قطع نظر دیا جانا ضروری ہے: ماخذ <a href="https://www.cdc.gov/vaccines/hcp/about-vis/index.html"target="_blank">https://www.cdc.gov/vaccines/hcp/about-vis/index.html</a>۔ AB - VIS تقریباً 40 زبانوں میں ترجمہ کیے جا چکے ہیں۔ یہ CDC کے شراکت دار کی ویب سائٹ پر مل سکتے ہیں، <a href="https://www.immunize.org/vis/"target="_blank">https://www.immunize.org/vis/</a>۔ ہر VIS کا ہر زبان میں ترجمہ نہیں کیا گیا ہے۔ AB - ویکسین کیوں لگوائیں؟ MMRV ویکسین خسرہ، ممپس، روبیلا، اور واریسیلا سے بچا سکتی ہے۔ خسرہ (M) بخار، کھانسی، ناک بہنا، اور سرخ، پانی بھری آنکھوں کا سبب بنتا ہے، جس کے بعد عام طور پر پورے جسم پر پھیلنے والے دانے نکل آتے ہیں۔ یہ دورے (اکثر بخار سے منسلک)، کان کے انفیکشن، اسہال، اور نمونیا کا سبب بن سکتا ہے۔ شاذ و نادر ہی، خسرہ دماغی نقصان یا موت کا سبب بن سکتا ہے۔ ممپس (M) بخار، سر درد، پٹھوں میں درد، تھکاوٹ، بھوک میں کمی، اور کانوں کے نیچے تھوک کے غدود کی سوجن اور نرمی کا سبب بنتا ہے۔ یہ بہرہ پن، دماغ اور/یا ریڑھ کی ہڈی کے غلاف کی سوجن، خصیوں یا بیضہ دانیوں کی تکلیف دہ سوجن، اور، بہت شاذ و نادر، موت کا سبب بن سکتا ہے۔ روبیلا (R) بخار، گلے کی سوزش، دانے، سر درد، اور آنکھوں میں جلن کا سبب بنتا ہے۔ یہ نوعمر اور بالغ خواتین میں سے تقریباً نصف میں گٹھیا (arthritis) کا سبب بن سکتا ہے۔ اگر کوئی عورت حاملہ ہونے کے دوران روبیلا کا شکار ہو جائے، تو اسے اسقاط حمل ہو سکتا ہے، یا بچہ سنگین پیدائشی نقائص کے ساتھ پیدا ہو سکتا ہے۔ واریسیلا (V)، جسے "چکن پاکس" بھی کہا جاتا ہے، بخار، تھکاوٹ، بھوک میں کمی، اور سر درد کے علاوہ خارش والے دانوں کا سبب بنتا ہے۔ یہ جلد کے انفیکشن، نمونیا، خون کی نالیوں کی سوزش، دماغ اور/یا ریڑھ کی ہڈی کے غلاف کی سوجن، اور خون، ہڈیوں، یا جوڑوں کے انفیکشن کا سبب بن سکتا ہے۔ کچھ لوگ جنہیں چکن پاکس ہوتا ہے، سالوں بعد "شنگلز" (جسے ہرپیز زوسٹر بھی کہا جاتا ہے) نامی ایک تکلیف دہ دانے کا تجربہ کرتے ہیں۔ MMRV کے ساتھ ویکسین لگوانے والے زیادہ تر لوگ زندگی بھر محفوظ رہیں گے۔ ویکسینز اور ویکسینیشن کی بلند شرحوں نے ان بیماریوں کو امریکہ میں کہیں کم عام بنا دیا ہے۔ AN - cdc:258358 CY - Atlanta, Georgia KW - Vaccines KW - Measles / prevention & control KW - Chickenpox KW - Rubella / prevention & control KW - Chickenpox Vaccine KW - Chickenpox / prevention & control KW - Measles KW - Measles-Mumps-Rubella Vaccine / adverse effects KW - Mumps KW - Measles-Mumps-Rubella Vaccine KW - Rubella KW - Mumps / prevention & control KW - Chickenpox Vaccine / adverse effects KW - Varicella KW - Vaccines KW - Measles KW - Measles / prevention & control KW - Mumps KW - Mumps / prevention & control KW - Rubella KW - Rubella / prevention & control KW - Chickenpox KW - Chickenpox / prevention & control KW - Chickenpox Vaccine KW - Chickenpox Vaccine / adverse effects KW - Measles-Mumps-Rubella Vaccine KW - Measles-Mumps-Rubella Vaccine / adverse effects LA - urd PB - Centers for Disease Control and Prevention (U.S.) PY - 08/06/2021 T3 - Vaccine Information Statement TI - MMRV ویکسین (خسرہ، ممپس، روبیلا، اور واریسیلا): جو آپ کو جاننا ضروری ہے [2021] UR - https://stacks.cdc.gov/view/cdc/258358 ER -
Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021]

Centers for Disease Control and Prevention (U.S.)

08/06/2021 | Vaccine Information Statement

VIS, або Інформаційна заява про вакцину, - це документ, підготовлений CDC, який інформує осіб, що отримують вакцину, - або їхніх батьків чи законних представників - про переваги та ризики вакцини, яку вони отримують. Усі постачальники вакцин, державні чи приватні, зобов'язані відповідно до Національного закону про травми внаслідок дитячих вакцин ht ...

07/29/2026

Supporting Files

Title : Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021] Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : 08/06/2021 Pages in Document : 2 pdf pages Series : Vaccine Information Statement;Інформаційний листок про вакцину; URL : https://stacks.cdc.gov/view/cdc/258357
Centers for Disease Control and Prevention (U.S.) (2021). Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021].

Centers for Disease Control and Prevention (U.S.) "Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021]" (2021)

Centers for Disease Control and Prevention (U.S.) "Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021]" , 2021
Export RIS Citation Information. TY - Array A2 - Centers for Disease Control and Prevention (U.S.) AB - VIS, або Інформаційна заява про вакцину, - це документ, підготовлений CDC, який інформує осіб, що отримують вакцину, - або їхніх батьків чи законних представників - про переваги та ризики вакцини, яку вони отримують. Усі постачальники вакцин, державні чи приватні, зобов'язані відповідно до Національного закону про травми внаслідок дитячих вакцин <a href="https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapXIX-part2-subpartc-sec300aa-26.pdf"_blank">(NCVIA - 42 U.S.C. § 300aa-26)</a> надавати пацієнту (або батькам чи законному представнику) відповідну VIS перед кожною дозою конкретних вакцин. Відповідна VIS має бути надана перед вакцинацією, а також перед кожною дозою в межах серії з кількох доз. Вона має надаватися незалежно від віку отримувача: за матеріалами <a href="https://www.cdc.gov/vaccines/hcp/about-vis/index.html"target="_blank">https://www.cdc.gov/vaccines/hcp/about-vis/index.html</a>. AB - VIS перекладено приблизно 40 мовами. Їх можна знайти на вебсайті партнера CDC, <a href="https://www.immunize.org/vis/"target="_blank">https://www.immunize.org/vis/</a>. Не кожна VIS перекладена всіма мовами. AB - Навіщо робити щеплення? Вакцина MMRV може запобігти кору, паротиту, краснусі та вітряній віспі. КІР (M) спричиняє гарячку, кашель, нежить і почервоніння та сльозотечу очей, за якими зазвичай слідує висип, що покриває все тіло. Він може призвести до судом (часто пов'язаних із гарячкою), вушних інфекцій, діареї та пневмонії. У рідкісних випадках кір може спричинити ураження мозку або смерть. ПАРОТИТ (M) спричиняє гарячку, головний біль, біль у м'язах, втому, втрату апетиту, а також набряк і болючість слинних залоз під вухами. Він може призвести до глухоти, набряку мозку та/або оболонок спинного мозку, болючого набряку яєчок або яєчників і, дуже рідко, смерті. КРАСНУХА (R) спричиняє гарячку, біль у горлі, висип, головний біль і подразнення очей. Вона може спричинити артрит у до половини дівчат-підлітків та дорослих жінок. Якщо жінка захворіє на краснуху під час вагітності, у неї може статися викидень, або дитина може народитися з серйозними вродженими вадами. ВІТРЯНА ВІСПА (V), яку також називають «вітрянкою», спричиняє свербіжний висип, а також гарячку, втому, втрату апетиту та головний біль. Вона може призвести до шкірних інфекцій, пневмонії, запалення кровоносних судин, набряку мозку та/або оболонок спинного мозку, а також інфікування крові, кісток або суглобів. У деяких людей, які перехворіли на вітрянку, через роки з'являється болючий висип, що зветься «оперізувальний лишай» (також відомий як herpes zoster). Більшість людей, вакцинованих MMRV, будуть захищені на все життя. Вакцини та високий рівень вакцинації значно знизили поширеність цих хвороб у Сполучених Штатах. AN - cdc:258357 CY - Atlanta, Georgia KW - Measles / prevention & control KW - Vaccines KW - Chickenpox KW - Rubella / prevention & control KW - Chickenpox Vaccine KW - Chickenpox / prevention & control KW - Measles KW - Measles-Mumps-Rubella Vaccine / adverse effects KW - Mumps KW - Rubella KW - Measles-Mumps-Rubella Vaccine KW - Mumps / prevention & control KW - Chickenpox Vaccine / adverse effects KW - Varicella KW - Vaccines KW - Measles KW - Measles / prevention & control KW - Mumps KW - Mumps / prevention & control KW - Rubella KW - Rubella / prevention & control KW - Chickenpox KW - Chickenpox / prevention & control KW - Chickenpox Vaccine KW - Chickenpox Vaccine / adverse effects KW - Measles-Mumps-Rubella Vaccine KW - Measles-Mumps-Rubella Vaccine / adverse effects LA - ukr PB - Centers for Disease Control and Prevention (U.S.) PY - 08/06/2021 T3 - Vaccine Information Statement TI - Вакцина MMRV (кір, паротит, краснуха та вітряна віспа): що потрібно знати [2021] UR - https://stacks.cdc.gov/view/cdc/258357 ER -
MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021]

Centers for Disease Control and Prevention (U.S.)

08/06/2021 | Vaccine Information Statement

VIS ya da Aşı Bilgilendirme Bildirimi, CDC tarafından hazırlanan ve aşı olacak kişilere - ya da onların ebeveynlerine veya yasal temsilcilerine - aldıkları aşının fayda ve risklerini bildiren bir belgedir. Kamuya veya özel sektöre ait tüm aşı sağlayıcıları, Ulusal Aşı Çocukluk Yaralanması Yasası https://www.govinfo.gov/content/pkg/USCODE-2010-title ...

07/29/2026

Supporting Files

Title : MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021] Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : 08/06/2021 Pages in Document : 2 pdf pages Series : Vaccine Information Statement;Aşı Bilgi Beyanı; URL : https://stacks.cdc.gov/view/cdc/258356
Centers for Disease Control and Prevention (U.S.) (2021). MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021].

Centers for Disease Control and Prevention (U.S.) "MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021]" (2021)

Centers for Disease Control and Prevention (U.S.) "MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021]" , 2021
Export RIS Citation Information. TY - Array A2 - Centers for Disease Control and Prevention (U.S.) AB - VIS ya da Aşı Bilgilendirme Bildirimi, CDC tarafından hazırlanan ve aşı olacak kişilere - ya da onların ebeveynlerine veya yasal temsilcilerine - aldıkları aşının fayda ve risklerini bildiren bir belgedir. Kamuya veya özel sektöre ait tüm aşı sağlayıcıları, Ulusal Aşı Çocukluk Yaralanması Yasası <a href="https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapXIX-part2-subpartc-sec300aa-26.pdf"_blank">(NCVIA - 42 U.S.C. § 300aa-26)</a> uyarınca, belirli aşıların her dozundan önce hastaya (veya ebeveynine ya da yasal temsilcisine) uygun VIS'i vermekle yükümlüdür. Uygun VIS, aşılamadan önce verilmelidir ve çok dozlu bir serinin her dozundan önce verilmelidir. Aşı olacak kişinin yaşına bakılmaksızın verilmelidir: kaynak <a href="https://www.cdc.gov/vaccines/hcp/about-vis/index.html"target="_blank">https://www.cdc.gov/vaccines/hcp/about-vis/index.html</a>. AB - VIS'ler yaklaşık 40 dile çevrilmiştir. Bunlara, CDC'nin iş ortağı olan <a href="https://www.immunize.org/vis/"target="_blank">https://www.immunize.org/vis/</a> adresindeki web sitesinden ulaşılabilir. Her VIS her dile çevrilmiş değildir. AB - Neden aşı olunmalı? MMRV aşısı kızamık, kabakulak, kızamıkçık ve suçiçeğini önleyebilir. KIZAMIK (M) ateş, öksürük, burun akıntısı ve kızarık, sulanan gözlere neden olur; genellikle bunu tüm vücudu kaplayan bir döküntü izler. Nöbetlere (sıklıkla ateşle ilişkili), kulak enfeksiyonlarına, ishale ve zatürreye yol açabilir. Nadiren, kızamık beyin hasarına veya ölüme neden olabilir. KABAKULAK (M) ateş, baş ağrısı, kas ağrıları, yorgunluk, iştah kaybı ve kulakların altındaki tükürük bezlerinde şişlik ve hassasiyete neden olur. Sağırlığa, beyin ve/veya omurilik zarının şişmesine, testislerde veya yumurtalıklarda ağrılı şişliğe ve çok nadiren ölüme yol açabilir. KIZAMIKÇIK (R) ateş, boğaz ağrısı, döküntü, baş ağrısı ve göz tahrişine neden olur. Genç kız ve yetişkin kadınların yarısına kadarında eklem iltihabına (artrit) neden olabilir. Bir kadın hamileyken kızamıkçığa yakalanırsa düşük yapabilir veya bebek ciddi doğum kusurlarıyla dünyaya gelebilir. SUÇİÇEĞİ (V), "su çiçeği" olarak da bilinir, ateş, yorgunluk, iştah kaybı ve baş ağrısının yanı sıra kaşıntılı bir döküntüye neden olur. Cilt enfeksiyonlarına, zatürreye, kan damarlarının iltihaplanmasına, beyin ve/veya omurilik zarının şişmesine ve kan, kemik veya eklem enfeksiyonuna yol açabilir. Suçiçeği geçiren bazı kişiler yıllar sonra "zona" (herpes zoster olarak da bilinir) adı verilen ağrılı bir döküntü geçirir. MMRV ile aşılanan çoğu kişi ömür boyu korunur. Aşılar ve yüksek aşılanma oranları, bu hastalıkları Amerika Birleşik Devletleri'nde çok daha az görülür hale getirmiştir. AN - cdc:258356 CY - Atlanta, Georgia KW - Measles / prevention & control KW - Vaccines KW - Chickenpox KW - Rubella / prevention & control KW - Chickenpox Vaccine KW - Chickenpox / prevention & control KW - Measles KW - Measles-Mumps-Rubella Vaccine / adverse effects KW - Mumps KW - Rubella KW - Measles-Mumps-Rubella Vaccine KW - Mumps / prevention & control KW - Chickenpox Vaccine / adverse effects KW - Varicella KW - Vaccines KW - Measles KW - Measles / prevention & control KW - Mumps KW - Mumps / prevention & control KW - Rubella KW - Rubella / prevention & control KW - Chickenpox KW - Chickenpox / prevention & control KW - Chickenpox Vaccine KW - Chickenpox Vaccine / adverse effects KW - Measles-Mumps-Rubella Vaccine KW - Measles-Mumps-Rubella Vaccine / adverse effects LA - tur PB - Centers for Disease Control and Prevention (U.S.) PY - 08/06/2021 T3 - Vaccine Information Statement TI - MMRV Aşısı (Kızamık, Kabakulak, Kızamıkçık ve Suçiçeği): Bilmeniz Gerekenler [2021] UR - https://stacks.cdc.gov/view/cdc/258356 ER -
วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021]

Centers for Disease Control and Prevention (U.S.)

08/06/2021 | Vaccine Information Statement

VIS หรือ เอกสารข้อมูลวัคซีน (Vaccine Information Statement) คือเอกสารที่จัดทำโดย CDC เพื่อแจ้งข้อมูลแก่ผู้รับวัคซีน - หรือผู้ปกครองหรือผู้แทนตามกฎหมาย - เกี่ยวกับประโยชน์และความเสี่ยงของวัคซีนที่กำลังจะได้รับ ผู้ให้บริการวัคซีนทั้งหมด ไม่ว่าจะเป็นภาครัฐหรือเอกชน ต้องปฏิบัติตามกฎหมาย National Vaccine Childhood Injury Act https://www.govinfo.gov/cont ...

07/29/2026

Supporting Files

Title : วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021] Corporate Authors(s) : Centers for Disease Control and Prevention (U.S.) Published Date : 08/06/2021 Pages in Document : 2 pdf pages Series : Vaccine Information Statement;เอกสารข้อมูลวัคซีน; URL : https://stacks.cdc.gov/view/cdc/258355
Centers for Disease Control and Prevention (U.S.) (2021). วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021].

Centers for Disease Control and Prevention (U.S.) "วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021]" (2021)

Centers for Disease Control and Prevention (U.S.) "วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021]" , 2021
Export RIS Citation Information. TY - Array A2 - Centers for Disease Control and Prevention (U.S.) AB - VIS หรือ เอกสารข้อมูลวัคซีน (Vaccine Information Statement) คือเอกสารที่จัดทำโดย CDC เพื่อแจ้งข้อมูลแก่ผู้รับวัคซีน - หรือผู้ปกครองหรือผู้แทนตามกฎหมาย - เกี่ยวกับประโยชน์และความเสี่ยงของวัคซีนที่กำลังจะได้รับ ผู้ให้บริการวัคซีนทั้งหมด ไม่ว่าจะเป็นภาครัฐหรือเอกชน ต้องปฏิบัติตามกฎหมาย National Vaccine Childhood Injury Act <a href="https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2010-title42-chap6A-subchapXIX-part2-subpartc-sec300aa-26.pdf"_blank">(NCVIA - 42 U.S.C. § 300aa-26)</a> ในการมอบ VIS ที่เหมาะสมให้แก่ผู้ป่วย (หรือผู้ปกครองหรือผู้แทนตามกฎหมาย) ก่อนการฉีดวัคซีนแต่ละครั้งสำหรับวัคซีนชนิดที่กำหนด ต้องมอบ VIS ที่เหมาะสมก่อนการฉีดวัคซีน และต้องมอบก่อนการฉีดทุกครั้งในกรณีที่เป็นชุดวัคซีนหลายโดส ต้องมอบให้โดยไม่คำนึงถึงอายุของผู้รับวัคซีน: จาก <a href="https://www.cdc.gov/vaccines/hcp/about-vis/index.html"target="_blank">https://www.cdc.gov/vaccines/hcp/about-vis/index.html</a> AB - VIS ได้รับการแปลเป็นภาษาต่าง ๆ ประมาณ 40 ภาษา ซึ่งสามารถค้นหาได้จากเว็บไซต์ขององค์กรพันธมิตรของ CDC ที่ <a href="https://www.immunize.org/vis/"target="_blank">https://www.immunize.org/vis/</a> ไม่ใช่ทุก VIS ที่จะได้รับการแปลเป็นทุกภาษา AB - เหตุใดจึงควรฉีดวัคซีน? วัคซีน MMRV สามารถป้องกันโรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส โรคหัด (M) ทำให้เกิดไข้ ไอ น้ำมูกไหล และตาแดงมีน้ำตา ซึ่งมักตามมาด้วยผื่นที่กระจายไปทั่วร่างกาย อาจนำไปสู่อาการชัก (ซึ่งมักสัมพันธ์กับไข้) การติดเชื้อในหู ท้องเสีย และปอดบวม ในบางกรณีที่พบได้น้อย โรคหัดอาจทำให้สมองเสียหายหรือเสียชีวิตได้ โรคคางทูม (M) ทำให้เกิดไข้ ปวดศีรษะ ปวดกล้ามเนื้อ อ่อนเพลีย เบื่ออาหาร และต่อมน้ำลายใต้หูบวมและเจ็บ อาจนำไปสู่อาการหูหนวก สมองบวมและ/หรือเยื่อหุ้มไขสันหลังอักเสบ อัณฑะหรือรังไข่บวมและเจ็บปวด และในบางกรณีที่พบได้น้อยมากอาจถึงขั้นเสียชีวิต โรคหัดเยอรมัน (R) ทำให้เกิดไข้ เจ็บคอ ผื่น ปวดศีรษะ และระคายเคืองตา อาจทำให้เกิดโรคข้ออักเสบได้ในผู้หญิงวัยรุ่นและผู้ใหญ่มากถึงครึ่งหนึ่ง หากผู้หญิงเป็นโรคหัดเยอรมันขณะตั้งครรภ์ อาจแท้งบุตร หรือทารกอาจเกิดมาพร้อมความพิการแต่กำเนิดที่รุนแรง โรคอีสุกอีใส (V) หรือที่เรียกว่า "chickenpox" ทำให้เกิดผื่นคัน นอกเหนือจากไข้ อ่อนเพลีย เบื่ออาหาร และปวดศีรษะ อาจนำไปสู่การติดเชื้อที่ผิวหนัง ปอดบวม หลอดเลือดอักเสบ สมองบวมและ/หรือเยื่อหุ้มไขสันหลังอักเสบ และการติดเชื้อในกระแสเลือด กระดูก หรือข้อต่อ บางคนที่เคยเป็นอีสุกอีใสอาจเกิดผื่นที่เจ็บปวดเรียกว่า "งูสวัด" (หรือที่รู้จักกันในชื่อ herpes zoster) ในอีกหลายปีต่อมา คนส่วนใหญ่ที่ได้รับวัคซีน MMRV จะได้รับการป้องกันตลอดชีวิต วัคซีนและอัตราการฉีดวัคซีนที่สูงทำให้โรคเหล่านี้พบได้น้อยลงมากในสหรัฐอเมริกา AN - cdc:258355 CY - Atlanta, Georgia KW - Measles / prevention & control KW - Vaccines KW - Chickenpox KW - Rubella / prevention & control KW - Chickenpox Vaccine KW - Chickenpox / prevention & control KW - Measles KW - Measles-Mumps-Rubella Vaccine / adverse effects KW - Mumps KW - Rubella KW - Measles-Mumps-Rubella Vaccine KW - Mumps / prevention & control KW - Chickenpox Vaccine / adverse effects KW - Varicella KW - Vaccines KW - Measles KW - Measles / prevention & control KW - Mumps KW - Mumps / prevention & control KW - Rubella KW - Rubella / prevention & control KW - Chickenpox KW - Chickenpox / prevention & control KW - Chickenpox Vaccine KW - Chickenpox Vaccine / adverse effects KW - Measles-Mumps-Rubella Vaccine KW - Measles-Mumps-Rubella Vaccine / adverse effects LA - tha PB - Centers for Disease Control and Prevention (U.S.) PY - 08/06/2021 T3 - Vaccine Information Statement TI - วัคซีน MMRV (โรคหัด คางทูม หัดเยอรมัน และอีสุกอีใส): สิ่งที่คุณจำเป็นต้องรู้ [2021] UR - https://stacks.cdc.gov/view/cdc/258355 ER -

Previous Page Previous

821 - 840 / 1003

Next Page Next

Found an issue?

Send us an email at: